본문 바로가기

바이오스펙테이터

기사본문

MitoImmune Targets Intractable Respiratory Diseases Using Anti-oxidant and Anti-necrosis MIT

입력 2019-08-06 10:03 수정 2019-08-14 10:01

by Joungmin Cho

이 기사는 '프리미엄 뉴스서비스 BioS+' 기사입니다.
The company has introduced a mitochondria targeting substance of which its safety was validated through Phase 1 clinical trial by LG Chemical, which will accelerate clinical development of IPF, severe

▲CEO Kim soon ha

MitoImmune Therapeutics is one of the few domestic companies specializing in mitochondria targeting treatment drugs. CEO Kim soon ha developed a Mitochondria-targeting Indole-based Technology (MIT) platform that suppresses inflammation and necrosis of cells by regulating production of active oxygen and accumulation of calcium in mitochondria at LG Chemical (the successor of LC Life Sciences).

MitoImmune Therapeutics Co., Kr, founded by CEO Kim soon ha in 2018, has introduced the MIT platform from LG Chemical and is now accelerating efforts for clinical development and commercialization. CEO Kim said, "I decided to establish my own company to create an environment where I could concentrate myself fully on development of MIT flatform." The strategy of MitoImmune Therapeutics is to develop a pipeline by targeting a substance whose safety has been validated through non-clinical trial and Phase 1 clinical trial solely on development of intractable respiratory disease-targeting treatments.

CEO Kim said, "First of all, we are going to develop pipeline drugs that can be selected as orphan drugs by focusing on intractable diseases as target indications in order to produce quick achievements such as speedy evaluation and early approval.”

◇MIT regulates the release of reactive oxygen and accumulation of calcium inside mitochondria to suppress inflammation and necrosis....

'프리미엄 뉴스서비스 BioS+'는 독자들에게 가치(value)있는 기사를 제공합니다.
추가내용은 유료회원만 이용할 수 있습니다.
회원이시면 로그인 해주시고, 회원가입을 원하시면 클릭 해주세요.
카카오스토리로 기사 공유하기